Radiotherapy increases the survival rate of 20.9%of esophageal cancer, and immunotherapy brings long -term hope of survival

Text/Picture Yangcheng Evening News all -media reporter Zhang Hua

On August 20th, the "Report on the Status of Radiotherapy Survival of Patients with Surgery Patients in Chinese esophageal & Types" (hereinafter referred to as "Report") was officially released. The report was led by Professor Wang Luhua, Dean of Shenzhen Hospital, Shenzhen Hospital of the Academy of Medical Sciences, and Professor Zhao Hailu, Director of Radi Therapy Center of Fudan University Affiliated Cancer Hospital, and led them. Executive secretary is supported by 15 clinical experts from 14 provincial hospitals across the country.

"Report on the Status Report of Radi -Survival Survival Survival of Chinese esophageal scale carcinoma" public release session online

14 radiation therapy centers provide more than 3,000 patients with real world data

Esophageal cancer is a common tumor in my country, and the incidence and mortality accounted for more than half of the world. Professor Wang Luhua said in an interview with reporters that most of the patients diagnosed in my country are mostly in the middle and late stages, and the proportion of patients with surgical patients can occupy a large proportion. Therefore, radiotherapy plays an important role in treating such patients for treatment. However, in clinical practice, due to the low knowledge of radiotherapy, this important treatment method in the past was often ignored or forgotten.

This survey is the first and the largest samples so far in my country. The survey involving a survey report that involves the treatment of immunotherapy in many medical centers in China in the entire region of China. As well as post -examination after radiotherapy, inter -provincial medical treatment, etc., it focuses on investigating the relevant content of the quality of life of patients after radiotherapy after radiotherapy. Professor Wang Luhua said, "14 units nationwide, the research lasted for nearly one year, and included 3060 patients in the analysis. It summarized the real survival of patients with surgical esophageal carcinoma from 2015-2016, which is precious."

The five -year survival rate of patients with radiotherapy reaches 30.0%

According to the "Report", the total 5-year survival rate was 30%of the total 5-year survival rate of patients receiving radical chemotherapy (immune drug therapy) from 2015-2016. Professor Zhao Happiness said that with the advancement of time, the 5 -year survival rate after esophageal cancer radiotherapy has been increased by 10%in the 1980s and 1990s, 20%in the early 21st century, and 30%of the survey. 40%of the report. This fully illustrates that radiotherapy is one of the treatment methods of esophageal cancer. With the advancement of radiotherapy technology and the rapid development of new chemotherapy and immunity, the cure rate of esophageal cancer radiotherapy is increasing.

During the treatment of esophageal cancer, patients still have tangles about choosing surgical treatment or radiotherapy schemes, and most patients are more inclined to choose surgical treatment schemes. Professor Wang Xin said that in recent years, more and more studies have shown that patients with esophageal cancer with good radiotherapy treatment do not need to perform surgical resection, and they can also achieve the same effect as surgery. The biggest advantage of radiotherapy in esophageal cancer is to retain the function of the esophagus, especially for the upper or neck esophageal cancer with a high tumor position. The surgery needs to be completely removed, and the radiotherapy can retain the laryngeal function.

Among the patients who survive, more than half have returned to normal life

The "Report" shows that about 70%-80%of patients with esophageal cancer who have survived for a long time after radiotherapy are satisfied with or quite satisfied with the quality of life, and they are confident in fighting the disease. And more than half of patients can return to normal work and life after radiotherapy. It can be seen that radiotherapy is a promising treatment strategy.

It is worth noting that the "Report" also pointed out that the survival of patients with different radiotherapy technologies and different chemotherapy schemes are significantly different. Professor Zhao Happy believes that the main cause of this situation is that the number of cancer patients has continued to increase in recent years, but the shortage of domestic radiotherapy equipment and radiotherapy experts has caused radiotherapy applications to be far from enough. What is, this situation is particularly prominent in developed areas. The National Cancer Center has issued a guide to the quality control of radiation therapy in 2017, urging all units to implement strict quality control standards, which will play a significant role in improving the precision of radiotherapy and promoting the standardization of the industry. In addition, the widespread application of 5G has promoted the development of remote radiotherapy technology, which can bring the same high -quality radiotherapy resources to more regions that lack resources and bring well -being to more cancer patients.

There are more "new weapons" in esophageal cancer treatment

The "Report" also discussed the application of immunotherapy. Professor Zhao Happle said that with the rise of innovative treatment methods such as immunotherapy, esophageal cancer treatment not only has more "new weapons", but also causes it to cause it, but also triggers it, but also triggered it. More exploration and discussion of new therapeutic concepts such as accurate immunization and radiotherapy combined immunity.

It is reported that in 2020, China's first esophageal cancer immunotherapy drug Paborzab was approved. In the 2022 "CSCO esophageal cancer diagnosis and treatment guidelines", the first -line treatment plan for advanced esophageal cancer of Paborizumab combined with chemotherapy was also used as the highest -level I -level recommendation, which laid the new standard treatment for patients with first -line esophageal cancer.

Source | Yangcheng Evening News · Yangcheng School

Responsible | Niu Zhijie

- END -